1. |
|
|
2. |
- Nassar, R., et al.
(author)
-
A global inventory of stratospheric chlorine in 2004
- 2006
-
In: Journal of Geophysical Research. - 0148-0227 .- 2156-2202. ; 111:22
-
Journal article (peer-reviewed)abstract
- Total chlorine (CITOT) in the stratosphere has been determined using the Atmospheric Chemistry Experiment Fourier Transform Spectrometer (ACE-FTS) measurements of HCl, ClONO2, CH3Cl, CCl4, CCl3F (CFC-11), CCl2F2 (CFC-12), CHClF2 (HCFC-22), CCl2FCClF2 (CFC-113), CH3CClF2 (HCFC-142b), COClF, and ClO supplemented by data from several other sources, including both measurements and models. Separate chlorine inventories were carried out in five latitude zones (60°-82°N, 30°-60°N, 30°S-30°N, 30°-60°S, and 60°-82°S), averaging the period of February 2004 to January 2005 inclusive, when possible, to deal with seasonal variations. The effect of diurnal variation was avoided by only using measurements taken at local sunset. Mean stratospheric ClTOT values of 3.65 ppbv were determined for both the northern and southern midlatitudes (with an estimated 1σ, accuracy of ±0.13 ppbv and a precision of ±.09 ppbv), accompanied by a slightly lower value in the tropics and slightly higher values at high latitudes. Stratospheric ClTOT profiles in all five latitude zones are nearly linear with a slight positive slope in ppbv /km. Both the observed slopes and pattern of latitudinal variation can be interpreted as evidence of the beginning of a decline in global stratospheric chlorine, which is qualitatively consistent with the mean stratospheric circulation pattern and time lag necessary for transport.
|
|
3. |
- de Jong, F. A., et al.
(author)
-
Irinotecan-induced diarrhea : functional significance of the polymorphic ABCC2 transporter protein
- 2007
-
In: Clinical Pharmacology and Therapeutics. - : Springer Science and Business Media LLC. - 0009-9236 .- 1532-6535. ; 81:1, s. 42-49
-
Journal article (peer-reviewed)abstract
- Interindividual pharmacokinetic variability of the anticancer agent irinotecan is high. Life-threatening diarrhea is observed in up to 25% of patients receiving irinotecan and has been related with irinotecan pharmacokinetics and UGT1A1 genotype status. Here, we explore the association of ABCC2 (MRP2) polymorphisms and haplotypes with irinotecan disposition and diarrhea. A cohort of 167 Caucasian cancer patients who were previously assessed for irinotecan pharmacokinetics (90-min infusion given every 21 days), toxicity, and UGT1A1*28 genotype were genotyped for polymorphisms in ABCC2 using Pyrosequencing. Fifteen ABCC2 haplotypes were identified in the studied patients. The haplotype ABCC2*2 was associated with lower irinotecan clearance (28.3 versus 31.6 l/h; P=0.020). In patients who did not carry a UGT1A1*28 allele, a significant reduction of severe diarrhea was noted in patients with the ABCC2*2 haplotype (10 versus 44%; odds ratio, 0.15; 95% confidence interval, 0.04–0.61; P=0.005). This effect was not observed in patients with at least one UGT1A1*28 allele (32 versus 20%; odds ratio, 1.87; 95% confidence interval, 0.49–7.05; P=0.354). This study suggests that the presence of the ABCC2*2 haplotype is associated with less irinotecan-related diarrhea, maybe as a consequence of reduced hepatobiliary secretion of irinotecan. As the association was seen in patients not genetically predisposed at risk for diarrhea due to UGT1A1*28, confirmatory studies of the relationships of ABCC2 genotypes and irinotecan disposition and toxicity are warranted.
|
|
4. |
|
|
5. |
|
|